All In Biotech

Drug Trial Radar · NCT06733402

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A, Inc.) to Aklief® Cream (US REFERENCE LISTED DRUG), Aklief Cream (REFERENCE PRODUCT) and Each Active Treatment to a Placebo Control in the Treatment of Acne Vulgaris.

Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,000

Actual

Start

Jun 20, 2024

Primary completion

Jun 20, 2024

Study completion Nov 9, 2024

Sponsor

Sponsor type
Industry
First posted
Dec 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the efficacy, therapeutic equivalence and safety of Trifarotene Cream 0.005% (Taro Pharmaceuticals U.S.A., Inc.) and US Reference Listed Drug, Canadian Reference Product over the placebo control in the treatment of acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • Trifarotene Cream 0.005%Drug

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

  • AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUGDrug

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

  • AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCTDrug

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

  • PlaceboDrug

    A thin layer of the investigational product will be self-applied to the affected areas of the face once daily at bedtime.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstrate the therapeutic equivalence, efficacy and safety of the Investigational ProductTime frame: Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taro Pharmaceuticals USA Inc.

    Hawthorne, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.